
|Articles|May 20, 2020
ASCRS 2020: Intraocular dexamethasone, moxifloxacin vs topical regimen
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' David Hutton speaks with John A. Hovanesian, MD, about the highlights of his presentation on patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin versus a topical regimen, during the 2020 ASCRS virtual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
The Residency Report: Cardiovascular risk scores as a window into ocular disease
3
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
4
FDA guidance to help accelerate cell and gene therapies
5





















